Kornimate/medical-research-clean huggingface dataset:
prevalence of mast cell activation syndrome in patients with eds with digestive disorders

Conditions: Ehlers Danlos Hypermobile Syndrome

Summary: the aim of the study is to confirm the association between hypermobile ehlers danlos syndrome (heds) and mast cell activation syndrome (mcas) in patients with digestive disorders managed in allergology departments.


Eligibility criteria:
inclusion criteria: * with hypermobile ehlers danlos syndrome * with digestive disorders * 14 years of age or older (minimum age for the mos-sf 36 questionnaire) * able to answer the questionnaires * whose participation in a day hospital at saint vincent de paul dedicated to the assessment of "functional digestive pain" is planned * who do not object to the use of their health data for research purposes additional criteria for minors : - no objection to the use of health data for research purposes by parents/guardians exclusion criteria: * under guardianship or curatorship * having taken a long-term high-dose antihistamine treatment (h1 or h2) during the last two months, according to the following thresholds : * desloratadine (\>5 mg/jour) * bilastine (\>20 mg/jour) * cetirizine (\>20 mg/jour) * ebastine (\>10 mg/jour) * fexofenadine (\>150 mg/jour) * levocetirizine (\>5 mg/jour) * loratadine (\>10 mg/jour) * exocetiridine (5 mg/jour) * mizolastine (\>10 mg/jour) * rupatadine (\>10 mg/jour) * polaramine (\>10 mg/jour) * oxomemazine (\>2 mg/jour) * hydroxyzine (\>25 mg/jour) * doxylamine (\>15 mg/jour) * cimetidine (\>200 mg/jour) * patients deprived of liberty, pregnant or nursing women

Keywords: genetic disease collagen abnormality nausea heartburn ehlers danlos hypermobile syndrome mast cell activation syndrome (mcas) allergology
cycling-based priming coordination training for enhancing ataxia recovery and brain plasticity

Conditions: Spinocerebellar Ataxias

Summary: effective walking and balance require not only lower limb muscle strength but also coordinated movement. for individuals with spinocerebellar ataxia (sca), rehabilitation strategies targeting coordination are essential to improving mobility and reducing the burden on caregivers. however, evidence-based rehabilitation approaches for ataxia remain limited. recent studies suggest that improvements in motor learning are often accompanied by changes in cortical excitability. abnormal cortical excitability in sca patients may hinder rehabilitation efforts, yet priming strategies-such as exercise or specific stimuli-have been shown to enhance motor learning by modulating cortical excitability. cycling exercise, in particular, has demonstrated the potential to improve coordination and influence cortical plasticity in individuals with sca, making it a promising priming strategy for coordination training. this clinical trial aims to: 1. investigate the priming effect and neural mechanisms of acute cycling exercise on coordination training in patients with sca. 2. explore the long-term impact of priming cycling training on cortical plasticity and functional mobility in individuals with sca. this study seeks to provide insights into optimized rehabilitation interventions that could enhance the quality of life and independence for people with sca.


Eligibility criteria:
inclusion criteria: - clinical diagnosis of sca. exclusion criteria: * musculoskeletal injuries on legs * osteoporosis. * any peripheral or central nervous system injury or disease patients.

Keywords: transcranial magnetic stimulation (tms) gait motor control motor learning
clarithromycin for the treatment of infections caused by nontuberculous mycobacteria (ntm)

Conditions: Nontuberculous Mycobacteria; Mycobacterium Avium Complex

Summary: use of oral clarithromycin for treatment of chronic lung disease due to mycobacterium avium-intracellulare and other non-tuberculous mycobacteria

oral clarithromycin for treatment of mac and other nontuberculous mycobacteria in adults with clinical history

Eligibility criteria:
inclusion criteria: * meet american thoracic society criteria for nontuberculous lung disease: two or more afb smear positive, culture positive sputums or bronchoscopic samples and/or two or more afb smear negative respiratory samples with moderate to heavy growth (2+-4+); abnormal cxr consistent with m. avium lung disease; absence of other potential lung pathogens (except for the coexistence of m. abscessus) * age 18 years and older exclusion criteria: * history of macrolide allergy * must not receive the antihistamines terfenadine (seldane) or astemizole (hismanal) while on clarithromycin * children less than 18 years of age * if a menstruating female, not pregnant and on adequate birth control

Keywords: mac ntm
a efficacy and safety trial of controlled release (cr) morphine in cancer patients

Conditions: Pain; Cancer

Summary: the purpose of the study is to determine the effect of egalet® morphine once daily compared to mst continus twice daily on pain intensity and use of rescue medication for break through pain after 2 weeks of treatment in patients with pain due to cancer.


Eligibility criteria:
inclusion criteria: * the patient has stable strong opioid use equipotent to 30-240 mg oral morphine sulphate daily for a minimum of 2 weeks prior to entering the run-in phase. * the patient has opioid-sensitive pain caused by active cancer. * the patient is aged minimum 18 years. exclusion criteria: * the patient has a life expectancy less than 2 months. * the patient has received chemotherapy or radiation therapy less than 4 weeks prior to entering run-in phase * patients with medical conditions contraindicating morphine treatment * the patient has hepatic disease or impaired kidney function * the patient is taking monoamine oxidase inhibitors (maois) or has taken a maoi within two weeks prior to entering baseline. * the patient is taking other opioid agonists or antagonists, zidovudine or cimetidine.
functional movement analysis of handball players

Conditions: Injuries; Sports Physical Therapy

Summary: relationship of functional movement analysis with injury history and athletic parameters in handball athletes abstract objectives: handball is a popular sport in many countries. there is lack of knowledge about handball athlete's functional movement capacity. the aim of this study is to investigate the functional movement screen (fms™) scores, to evaluate the injury risks of handball athletes and to determine its relationship with athletic performance. design: observational study. methods: a total of 51 professional handball players in turkey were included in this study. the sport-specific features and demographic data were recorded. the functional movement analysis was performed and agility and balance and force were evaluated.

in august 2018, same evaluations will be done for same individuals.

Eligibility criteria:
inclusion criteria: * become a team licensed handball athlete between ages 16-35 * have not had a surgical operation involving the musculoskeletal system in the last six months * not having an obstacle to the realization of the tests to be carried out in the study * volunteering to participate in the work exclusion criteria: * if feeling any discomfort during the tests * do not want to go on study

Keywords: athletic performance functional movement screen handball athletes injury prevention injury history
oxandrolone multiligament knee

Conditions: Ligament Tear Knee

Summary: this study is about healing after a rmultiligament knee reconstruction procedure. we hope to learn if a biologic medication: oxandrolone, a synthetic derivative of the human hormone testosterone (the principal male sex hormone and an anabolic steroid), given for 12 weeks is effective in aiding in the healing process and restoring muscle mass.


Eligibility criteria:
inclusion criteria: • patients with mri proven multiligament knee injury scheduled to undergo multiligament knee reconstruction exclusion criteria: * patients with prior ipsilateral knee surgery * untreated diabetes mellitus * pituitary tumor * rheumatoid arthritis * uncontrolled hypertension * congestive heart failure * myocardial infarction within the past 6 months * end-stage renal disease * liver enzymes two times the normal value * dvt within the past 6 months * disorder of the coagulation system * currently taking anticoagulation * prior or current use of anabolic steroids * chromosomal disorders * prostate cancer * breast cancer * hypercalcemia * patients with copd not responsive to bronchodilators * patients with known liver disease * patients at risk for liver tumors * severe hyperlipidemia * patients taking medications that interfere with testosterone production or function, including but not limited to 5α-reductase inhibitors, acetaminophen (tylenol, others), cholesterol lowering

Keywords: oxandrolone testosterone anabolic steroid
tolerance assesment of the usage of an analgesic dose of esketamine for treatment of moderate to intense pain in an emergency departement

Conditions: Pain, Acute

Summary: ketamine has been used for several years in emergency departments for analgesic purposes. its ease of use and its analgesic effect have been demonstrated in several studies. nevertheless, this molecule is not devoid of side effects, in particular the very frequent occurrence of nausea, vomiting, anxiety, an overall feeling of discomfort and more rarely hallucinations, feelings of unreality, or tachycardia. recently, esketamine, used as an anesthetic but also in the usa as an antidepressant, has obtained its marketing authorization in the management of moderate to severe pain. esketamine corresponds to the s-(-)-ketamine enantiomer. like ketamine, it acts as a non-competitive antagonist of the n-methyl-d-aspartate (nmda) receptor but unlike ketamine does not interact, with the sigma receptors responsible for hallucinations and delusional symptoms. esketamine aimed at anesthetic is about twice as potent as ketamine and would also be eliminated more quickly. studies suggest that at equivalent doses, esketamine would be better tolerated than the ketamine usually used in emergency departments. in this study, the tolerance of esketamine used at analgesic doses for treatment of moderate to severe pain will be assessed in an emergency departement a wider usage of esketamine for analgesia purpose in emergency departments is expected, with a better tolerance for the patients compared to ketamine


Eligibility criteria:
inclusion criteria: * age is 18 years old or more * moderate to severe pain as assessed by the patient with a verbal numerical rating scale (nrs) of 6/10 or more ; nrs goes from 0 (no pain) to 10 (the worst pain imaginable) * physician has decided to use esketamine * patient is not opposed to enroll in the study after having been informed, as attested by the physician in the patient's file exclusion criteria: * adult under juridic protection, under guardianship, under curatorship * patient unable to express his consent * patient deprived of liberty by a judicial or administrative decision * pregnant, parturient or nursing mother * patients physically or mentally unable to answer the questionnaire * typical kidney colic pain

Keywords: analgesia emergency department esketamine
tips microspheres for perianal fistula

Conditions: Perianal Fistula

Summary: phase of investigation: first-in-human feasibility study objectives: primary objective: demonstration that tips microspheres do not compromise the clinical condition or safety of the patient. secondary objective: to demonstrate that tips microspheres facilitate natural healing in the context of perianal fistula. type of investigation: first-in-human single site, open label, feasibility study to assess the safety of tips microspheres in perianal fistulas and indicative functionality. investigation design and methods: first-in-human single delivery of a bioabsorbable device to treat perianal fistula. a standard of care internal flap procedure performed to close the internal fistula opening and up to 300 mg of tips microspheres will be inserted into each perianal fistula. participants will be assessed for healing, inflammation, abscess, sepsis, pain and continence by clinical assessments, blood tests, mri and questionnaires.

tips microspheres are manufactured from gmp grade poly(lactide-co-glycolide) (plga) under good laboratory practice (glp) conditions. microspheres will be delivered into the fistula tract using the following procedure: i) tract identification with special emphasis on locating the internal and external openings using a fistula probe. ii) curettage to remove epithelium lining the tract and cleaning by irrigation with hydrogen peroxide and saline. iii) closure of the internal opening by means of a rectoanal advancement flap. iv) following device kit instructions, prepare a paste of tips microspheres with granugel. v) introduction of tips microsphere paste by back-filling. vi) retention of the microsphere paste using comfeel adhesive hydrocolloid dressing designed to remain in place for 1 - 14 days. each subject will receive a single administration of up to 300 mg of tips microspheres implanted into the fistula tract.

Eligibility criteria:
inclusion criteria: * age 18 years and above * cryptoglandular perianal fistula * high and low simple trans-sphincteric fistula exclusion criteria: * secondary fistula, including crohn's disease, carcinoma, radiotherapy, tuberculosis * evidence of branching fistula anatomy or cavity on mri * inter-sphincteric fistula * low trans-phincterictrans-sphincteric fistula amenable to simple fistulotomy * immunosuppressed patients * participants less than 18 years of age * unable to consent
balneotherapy; as a complementary way of maintaining cardiac health

Conditions: Osteoarthritis

Summary: balneotherapy has been defined as the use of thermal, mineral waters for medical purposes. to highlight its possible effects on cardiac health, echocardiographic parameters were retrospectively analysed before and after the treatment in adult-elderly osteoarthritis patients.

thermal therapies are mostly preferred by adult-elderly patients, and it is highly probable that known or hidden cardiovascular disease prevalences are higher among these patients. therefore, a cardiovascular examination may be required both before and after the intervention. to find out effects of bath therapy on echocardiographic parameters, patients who were consulted to cardiology outpatient clinic before and after the spa therapy were retrospectively investigated.

Eligibility criteria:
inclusion criterias: * having balneotherapy sessions 5 days a week for total of three weeks * having detailed echocardiography records exclusion criterias: * individuals who do not have detailed echocardiography records, * having history of major surgery, * cerebrovascular accident, * malignancy, * liver or renal failure, * immunodeficiency, * acute/chronic infection, * psychiatric disorders were exluded.

Keywords: balneotherapy echocardiography wellness heart
efficacy of time-limited psychodynamic psychotherapy and informed clinical management in bpd high mhs users

Conditions: Heavy MHS Use; General Psychopathology; Working Alliance

Summary: subjects affected with severe borderline personality disorder (bpd) are often heavy users of mental health services (mhs). this study evaluates the efficacy of the addition of sequential brief adlerian psychodynamic psychotherapy (sb-app) to the treatment-as-usual (tau) for bpd compared to the tau alone for a naturalistic group of heavy mhs users with bpd. the efficacy was evaluated after at 6 time points along a two years of follow-up. thirty-five outpatients eligible for the study were randomly assigned to two treatment groups (tau=17; sb-app=18). the clinical global impression (cgi) and the cgi-modified (cgi-m) for bpd, the global assessment of functioning (gaf), the state-trait anger expression inventory (staxi), and the symptom checklist-90 revised (scl-90-r) were administered at t1, t3, t6, t12, t18, and t24. at t12 also the working alliance inventory-short form (wai-s) was filled-in by participants and compared between groups. in the one-year follow-up the sb-app group did not receive any individual psychological support. mhs was specifically trained in bpd treatment and had regular supervisions. scores of the cgi, gaf, and staxi improved after 6 and 12 months, irrespective of treatment. sb-app group displayed a better outcome for impulsivity, suicide attempts, chronic feelings of emptiness and disturbed relationships. the results displayed a good stabilization during follow-up year even after the interruption of psychotherapy in the sb-app group. even though the tau for bpd applied to heavy msh users displayed some efficacy in reducing symptom expression and improving global functioning, the adjunct of a specific time-limited and focused psychotherapeutic treatment reached a better outcome. in particular the possibility of a focus on patients' personality functioning (sb-app) with a specific psychotherapeutic approach seemed to be more effective than the general support to social impairment offered by the tau approach.


Eligibility criteria:
inclusion criteria: (a) diagnosis of bpd according to dsm-iv-tr criteria; (b) age between 20 and 50 years; (c) heavy use of mhs during the year before the study - as defined below; and (h) signed informed consent. exclusion criteria: (d) acute full-syndrome axis i disorder requiring urgent inpatient treatment; (e) current substance dependence disorder; (f) moderate to severe mental retardation; (g) previous treatment with structured psychotherapy;

Keywords: bpd mhs heavy users sequential psychotherapy
effects of different area of internal limiting membrane peeling (ilm) peeling on anatomical outcomes in macular hole surgery

Conditions: Macular Hole

Summary: the purpose of this study is to determine the effects of two different internal limiting membrane (ilm) peeling area on anatomical closure outcomes after macular hole surgery measured by optical coherence tomography (oct).


Eligibility criteria:
inclusion criteria: * patients with imh * patients signed the informed consent form (icf) * patients with course of imh less than 3 years exclusion criteria: * patients with hyper myopia * patients with traumatic macular hole * accompanied or secondary of other fundus disease * open or reopen after receiving mh surgery * patients with retinal detachment * received vitrectomy due to other diseases * glaucoma cannot be controled by medication * patients with other retinal or choroidal disease that may affect va * poor patients compliance * poor condition that cannot undertake the surgery * dioptric media opacities which make it difficult to exam fundus or measure on oct
valganciclovir for treatment of cytomegalovirus infection in solid organ transplant patients

Conditions: Cytomegalovirus Infection

Summary: the objectives of this study were: 1. to demonstrate the efficacy/safety of a short therapeutic strategy of treatment of cmv infection/disease in sot patients (kidney, liver and heart recipients) based on 21 days of treatment. 2. to compare the exposure to ganciclovir, at steady state, after oral valganciclovir with respect to ganciclovir given intravenously (i.v.). 3. evaluate the security of this treatment with valganciclovir.

sot recipients (kidney, liver and heart transplant) presenting cmv infection or disease were eligible for inclusion if they were ≥18 years of age and presented a positive cmv antigenemia (pp65) defined as ≥ 20positive cells/105 peripherical blood mononuclear cells (pbmc). patients excluded were those with severe cmv tissue invasive disease, unable to receive oral medication, absolute neutrophil counts less than 500/ mm3, platelets \<25000 platelets/mm3, hemoglobin\< 80g/l or estimated glomerular filtration rate\< 10 ml/min (according to the cockcroft-gault formula). patients received a short induction treatment with ganciclovir i.v (cymevene®; f. hoffmann-la roche ltd, basel, switzerland) at the dose of 5 mg/kg/12h, by a peripherical vein infusion of one hour, during 5 days followed by treatment with oral valganciclovir (valcyte®; f. hoffmann-la roche ltd, basel, switzerland) at 900 mg/12h during 16 days, after meals, until complete a total of 21 days of treatment. in patients with impaired renal function ganciclovir i.v. and oral valganciclovir doses were adjusted at each visit according to estimated glomerular filtration rate (gfr) by cockcroft-gault equation, as recommended by the manufacturer.

Eligibility criteria:
inclusion criteria: * ≥18 years of age, solid organ transplant recipients. * presented a cmv infection demonstrated by cmv antigenemia (pp65) defined as ≥ 20positive cells/105 peripherical blood mononuclear cells (pbmc). * gave written informed consent. exclusion criteria: * hiv patients. * multiorganic transplant. * severe cmv tissue invasive disease. * unable to receive oral medication. * absolute neutrophil counts less than 500/ mm3. * platelets \<25000 platelets/mm3. * hemoglobin\< 80g/l. * estimated glomerular filtration rate\< 10 ml/min (according to the cockcroft-gault formula)

Keywords: valganciclovir ganciclovir pharmacokinetics solid organ transplantation transplant
comparison of autologous mesenchymal stem cells and mononuclear cells on diabetic critical limb ischemia and foot ulcer

Conditions: Autologous Transplantation; Diabetic Foot

Summary: objective: to compare the effect and safety of autologous transplantation of bone marrow mesenchymal stem cells(mscs) and mononuclear cells(mncs) on diabetic patients with critical limb ischemia and foot ulcer. methods: patients were randomized into the a group and the b group by use of a randomization table. one lower limb in a group or in b group was selected randomly for mscs or mncs transplantation as mscs or mncs group, the other lower limb in the same patient was selected for placebo（normal saline ,ns）injection as ns group. the whole procedures of this clinical trial were blinded to both patients and investigators.patients in both groups received the same ordinary treatment. meanwhile, mscs and mncs were transplanted into the impaired lower limbs respectively. follow-up index include: efficacy (pain,ulcer healing rate, lower limb amputation rate and ,ankle-brachial index,transcutaneous oxygen pressure,magnetic resonance angiography) and safety (infection of the injection site, immunological rejection, and tumour generation).

research design and methods written informed consent was obtained from all subjects. type 2 diabetic patients with bilateral critical limb ischemia (ankle-brachial index, abi from 0.30 to 0.60) and at least with one foot ulcer, but without malignant tumor or gangrene above the ankle and/or severe coronary, cerebral and renal vascular disease, were eligible for the participation in this trial. eligible patients took part in this study on a voluntary basis. they were randomized into the a and b group by use of a randomization table. one lower limb in a group or in b group was selected randomly for bmmscs or bmmncs transplantation as bmmscs or bmmncs group, the other lower limb in the same patient was selected for placebo（normal saline ,ns）injection as ns group. the whole procedures of this clinical trial were blinded to both patients and investigators. preparation of human autologous serum preparation of mscs and mncs flow cytometric analysis examination of cells safety administration of therapy 5.0\*108\~5.0\*109 mscs and mncs were transplant into impaired lower limbs by intramuscular injection. observation index and assessment guidelines statistical analysis

Eligibility criteria:
inclusion criteria: * age from 40 to 70 years * type 2 diabetic patients * bilateral critical limb ischemia(abi from 0.30 to 0.60) * at least with one foot ulcer exclusion criteria: * dry gangrene above the ankle or moist gangrene * malignant tumor * severe coronary,cerebral and renal vascular disease

Keywords: mesenchymal stem cells mononuclear cells